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Abstract
Background and Aims: We studied the long-term outcome of patients with ulcerative colitis [UC] 
and primary non response [PNR] to infliximab and searched for predictors of colectomy in these 
patients.
Methods: This retrospective, multi-centre study included UC patients from three European referral 
centres, with PNR to infliximab defined as a lack of clinical improvement after the induction therapy, 
leading to drug discontinuation. Relapse, for patients who continued on biologicals after PNR to 
infliximab, was defined as drug discontinuation for PNR, loss of response, or serious adverse 
event. Serum infliximab concentrations at Weeks 2 and 6 were evaluated using an enzyme-linked 
immunosorbent assay [ELISA] developed in house.
Results: The study population consisted of 99 anti-tumour necrosis factor [TNF]-naïve patients 
with UC and PNR to infliximab. At the end of follow-up (median: 3.2 [interquartile range 1–6.3] 
years), 55 [55.6%] of these patients underwent colectomy. Multiple Cox regression analysis 
identified acute severe UC (hazard ratio [HR]: 24; 95% confidence interval [CI]: 2.5–231; p = 0.006], 
baseline C-reactive protein [CRP] > 5 mg/l [HR: 11; 95% CI: 2.1–58.8; p = 0.005], baseline albumin 
< 40 g/l [HR: 9.5; 95% CI: 1.3–71.4; p = 0.026], and infliximab concentration at Week 2 < 16.5 μg/ml 
[HR: 5.6; 95% CI: 1.1–27.8; p = 0.034] as independent predictors of colectomy. Regarding patients 
who continued on biologicals after PNR to infliximab, there was a marginally higher cumulative 
probability for relapse in patients switching to another anti-TNF agent compared with those 
swapping to vedolizumab [p logrank = 0.08].
Conclusions: About half of UC patients with PNR to infliximab will undergo colectomy. Patients 
with severe inflammation and low serum infliximab concetrations during the induction phase are 
at greatest risk.
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1. Introduction
Anti-tumour necrosis factor [TNF] therapy is an effective treatment 
for patients with inflammatory bowel disease [IBD], namely Crohn’s 
disease [CD] and ulcerative colitis [UC].1 Nevertheless, 10–30% of 
IBD patients show no clinical benefit and are considered as primary 
non-responders.2 The mechanisms underlying primary non-response 
[PNR] to anti-TNF therapy in IBD are not yet clearly defined.3 
However, data suggest that some of the mechanisms are similar to 
those involved in secondary loss of response [SLR] including phar-
macokinetic [PK] and/or pharmacodynamic [PD] issues.4 The former 
are characterised by undetectable or low serum drug concentrations 
due to an accelerated clearance of the drug in the systemic circula-
tion and/or local tissue, whereas the latter are associated with ade-
quate serum drug concentrations and a probable shift of the disease 
to a non TNF-driven inflammatory pathway.5
Currently, due to lack of relevant data, there are no clinical rec-
ommendations and/or guidelines on how to handle IBD patients 
with PNR to anti-TNF therapy and management remains therefore 
empirical. The only available data derive exclusively from small, 
observational, non-controlled studies that focus on the short-term 
efficacy of adalimumab in CD patients with PNR to infliximab.6,7,8,9 
Besides surgical treatment, which still remains a valid therapeutic 
option when dealing with IBD, in real-life clinical practice most phy-
sicians, will often attempt a switch to another anti-TNF agent or to 
another drug class, such as anti-adhesion molecule therapy.10,11
Preliminary data suggest that early measurement of drug and anti-
drug antibody concentrations, known as therapeutic drug monitoring, 
could help to better understand the mechanisms of PNR and ration-
alise patient management.12,13,14,15,16,17,18 Nevertheless, in contrast to 
SLR,19 relevant data that could determine whether switching within 
the same drug class or swapping [switching out of the drug class] is 
preferable after PNR to the first biological agent, are largely missing.20
The main goal of our study was to investigate the long-term out-
come of UC patients with PNR to infliximab and search for pre-
dictors of colectomy including infliximab concentrations during the 
induction therapy.
2. Materials and Methods
2.1. Study design, definitions, and patient 
population
This was a retrospective, observational, multi-centre study including 
consecutive, anti-TNF naïve patients with UC and PNR to infliximab 
induction therapy, between 1999 and 2013, from three European 
tertiary referral IBD centres: University Hospitals Leuven, Belgium; 
Evangelismos Hospital, Athens, Greece; and University Hospital, 
Université de Lorraine, Nancy, France. All patients’ data were reviewed 
from their paper and electronic medical records up to October 2014.
The decision or time to colectomy in all three hospitals was based 
on physician global assessment according to standard of care clini-
cal practice criteria. Typically, surgery is recommended in patients 
who fail or cannot tolerate continued medical therapy [including 
rescue therapy with biologicals] characterised by severe toxic symp-
toms [such as > 10 stools/day, continuous bleeding, abdominal pain, 
and fever] or severe complications [such as colonic perforation, life-
threatening gastrointestinal haemorrhage, and toxic megacolon] 
and/or have colorectal dysplasia or cancer.
Primary non-response to infliximab was defined as a lack of 
clinical improvement [based on physician global assessment] after 
induction therapy [Weeks 0-2-6, 5 or 10mg/kg, at least 2 infusions] 
leading to drug discontinuation.3,21 In the great majority of patients 
[n  =  79/99, 80%], severe inflammation necessitating drug discon-
tinuation was also confirmed by flexible sigmoidoscopy showing an 
endoscopic Mayo score of 2 or 3. Relapse for UC patients who con-
tinued on biologicals after PNR to infliximab, either by switching 
inside class [adalimumab, certolizumab pegol, and/or golimumab] 
or swapping [vedolizumab, etrolizumab, and/or other] was defined 
as drug discontinuation due to PNR, loss of response, or serious 
adverse event. For patients treated with investigational drugs only, 
open-label drug administrations were included in our analysis.
Serum samples from patients treated in the University Hospitals 
Leuven, Belgium, were prospectively collected just before an inflixi-
mab infusion at Weeks 2 [n = 42] and 6 [n = 37] and stored at -20°C. 
Patients gave written informed consent to participate in the institu-
tional review board-approved Flemish Study for Research on IBD, 
VLECC registry B322201213950 / S53684.
2.2. Serology
Infliximab concentrations and antibodies to infliximab [ATI] were meas-
ured using an in-house developed and clinically validated enzyme-linked 
Table 1. Baseline characteristics of the study population.
Patient characteristics N = 99
Male, [%] 65 [66]
Age at start of infliximab, median [IQR], years 40 [29–57]
Disease duration, median [IQR], yearsa 3 [1.1–9.1]
UC extension, [%]
Proctitis
Left-sided colitis
Pancolitis
2 [2]
39 [39]
58 [59]
Acute severe UC,b [%] 23 [23]
Smoking at baseline, [%] 6/73 [8]
Induction therapy with 10 mg/kg, [%] 13 [13]
Concomitant corticosteroids,c [%] 42 [42]
Concomitant immunomodulators,c [%] 37 [37]
Baseline BMI, median [IQR], kg/m2 22.1 [20.5–25.3]
Baseline CRP > 5 mg/l, [%] 31/54 [57]
Baseline CRP, median [IQR], mg/l 9 [2–19]
Baseline albumin, median [IQR], g/l 40.8 [37.5–44]
aFrom diagnosis to start of infliximab.
 bDefined as a serious, life-threating clinical condition necessitating hospi-
talisation according to the Truelove and Witts criteria.42
cCombination treatment during induction therapy.
Ulcerative colitis; BMI, body mass index; CRP, C-reactive protein; IQR, 
interquartile range.
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Figure  1. Kaplan-Meier colectomy-free survival curve of patients with 
ulcerative colitis and primary non-response to infliximab. PNR, primary non-
response.
2 K. Papamichael et al.
 by guest on M
ay 10, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
immunosorbent assay [ELISA] as previously described.22 The lower detec-
tion limits for infliximab concentrations and ATI were 0.3 µg/ml and 
1 µg/ml equivalents, respectively. ATI were not detectable in serum if inf-
liximab concentration was ≥ 0.3 µg/ml and were regarded as inconclusive 
for ATI. The upper limit of quantification [ULOQ] using standard dilu-
tions of 1/150 and 1/300 was 22.5 μg/ml. Samples with a drug concentra-
tion above the ULOQ were diluted up to 1/1200 until a result that fell 
within the linear phase of the standard curve of the assay was obtained.
Table 2. Variables associated with colectomy in patients with ulcerative colitis and primary non-response to infliximab.
Univariate analysis Multivariate analysis
Variables HR 95% CI p
[logrank]
HR 95% CI p
[logrank]
SN
[%]
SP
[%]
PPV
[%]
NPV
[%]
Male 0.997
Age at start of infliximab < 60 yearsa 0.101
Disease duration < 3.2 yeara 2.6 1.5–4.5  < 0.001
Smoking at baseline 0.113
Pancolitis 0.165
Acute severe UC [%] 6.6 2.8–15.1  < 0.001 24 2.5–231 0.006 74 50 31 86
Baseline albumin < 40 g/la 5.7 2.3–14.2  < 0.001 9.5 1.3–71.4 0.026 71 67 62 75
Baseline CRP > 5 mg/l 4.2 2–9.2  < 0.001 11 2.1–58.8 0.005 71 78 81 67
Induction therapy with 10mg/kg 0.555
Baseline BMI < 20.6 kg/m2a 0.093
Concomitant corticosteroids 2.1 1.2–3.8 0.007
Concomitant immunomodulators 0.728
Infliximab concentration < 16.5 μg/ml at Week 2a 5.4 2–14.6 0.001 5.6 1.1–27.8 0.034 80 70 60 86
Infliximab concentration < 5.3 μg/ml at Week 6a 14.6 3.7–57.4  < 0.001
UC, ulcerative colitis; BMI, body mass index; CI, confidence interval; NPV, negative predictive value; HR, hazard ratio; PPV, positive predictive value; SN, 
sensitivity; SP, specificity; CRP, C-reactive protein.
aCut-off based on receiver operating curve analysis [Supplementary Figure 1, available as Supplementary data at ECCO-JCC online].
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Figure  2. Kaplan-Meier curve demonstrating the cumulative probability for colectomy after primary non-response to infliximab stratified by concomitant 
corticosteroid treatment [A], disease duration [B], and acute severe ulcerative colitis [C]. UC, ulcerative colitis; PNR, primary non-response.
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Albumin and C-reactive protein [CRP] levels were measured at 
baseline and after the induction therapy by standard procedures. CRP 
≤ 5 mg/l and albumin levels 35–50 g/l were considered as normal.
2.3. Statistical analysis
Descriptive statistics were provided with medians and interquartile 
ranges [IQRs] for continuous variables, and frequency and percent-
ages for categorical variables.
A receiver-operating characteristic [ROC] analysis was per-
formed for age at start of infliximab, disease duration, baseline 
body mass index [BMI], serum albumin, and infliximab concen-
tration at Weeks 2 and 6 during the induction therapy, in order 
to trace thresholds associated with colectomy in UC patients fol-
lowing PNR to infliximab [Supplementary Figure 1, available as 
Supplementary data at ECCO-JCC online]. Optimal thresholds 
were chosen using the Youden index, which maximises the sum 
of the specificity and sensitivity of the ROC curve as previously 
described.12 Sensitivity [SN], specificity [SP], positive predic-
tive value [PPV], and negative predictive value [NPV] were also 
calculated.
Infliximab concentrations at Weeks 2 and 6 were compared 
between groups, using the Mann-Whitney U test. Serum infliximab 
concentrations were also categorised into quartiles. Rates of colec-
tomy were compared across baseline albumin and CRP levels and 
serum infliximab concentrations at Week 2 and 6 quartiles, using the 
chi-square test [linear-by-linear association].
The Kaplan-Meier method was used to estimate the propor-
tion of patients undergoing colectomy and the median time to 
colectomy. Univariate analysis using the logrank test was per-
formed to identify variables predicting a colectomy in UC patients 
after PNR to infliximab. To determine the independent effects of 
variables, multiple Cox proportional hazards regression analy-
sis was then performed, including variables with a p-value of < 
0.1 based on the Wald Backward selection method. The results 
were expressed as hazard ratios [HRs] with 95% confidence 
intervals [95% CI] followed by the corresponding p-value. Multi-
collinearity between infliximab concentrations at Weeks 2 and 6 
was assessed based on linear regression analysis and the variance 
inflation factor [VIF].
Relapse and PNR of an alternative anti-TNF drug treatment course 
was compared with those of a non-TNF agent in patients who con-
tinued on biologicals after PNR to infliximab, using the logrank test.
Results were considered statistically significant when p < 0.05. 
All statistical analyses were performed using the SPSS 23.0 software 
[SPSS, Chicago, IL, USA] and GraphPad Prism version 5.03 for 
Windows [GraphPad Software, San Diego, CA, USA].
3. Results
3.1. Study population
The study population consisted of 99 anti-TNF naïve patients with 
UC and PNR to infliximab. The majority of patients were male 
0
20
C
ol
ec
to
m
y-
fr
ee
 s
ur
vi
va
l (
%
)
0 2 4
Follow up after PNR to iniximab (years)
LogRank: p=0.001
Breslow: p=0.001
A
6 8 10 12
40
60
80
100
At risk: 27 21
Iniximab concentration, week 2 <16.5 µg/ml, n=15
Iniximab concentration, week 2 ≥16.5 µg/ml, n=27
15 12 7 6 6 4 3 3 1 0 0
15 6 5 5 4 3 2 1 0 0 0 0 0
0
20
C
ol
ec
to
m
y-
fr
ee
 s
ur
vi
va
l (
%
)
0 2 4
Follow up after PNR to iniximab (years)
Follow up after PNR to iniximab (years)
LogRank: p<0.001
Breslow: p<0.001
B
6 8 10 12
40
60
80
100
At risk: 28 22
Iniximab concentration ≥ 5.3 µg/mL at week 6, n=28
Iniximab concentration < 5.3 µg/mL at week 6, n=9
16 13 8 7 6 4 3 3 1 0 0
9 3 2 2 1 1 1 0 0 0 0 0 0
0
20
C
ol
ec
to
m
y-
fr
ee
 s
ur
vi
va
l (
%
)
0 2 4
Follow up after PNR to iniximab (years)
LogRank: p<0.001
Breslow: p=0.001
C D
6 8 10 12
40
60
80
100
At risk: 31 11 7 6 3 3 3 2 0 0 0 0 0
23 16 13 11 7 6 5 3 3 3 1 0 0
At risk: 27 20 16 13 8 7 6 4 3 3 1 0 0
21 6 3 3 2 2 2 1 0 0 0 0 0
Baseline CRP > 5 mg/l, n=31
Baseline CRP ≤ 5 mg/l, n=23
0
20
C
ol
ec
to
m
y-
fr
ee
 s
ur
vi
va
l (
%
)
0 2 4
LogRank: p<0.001
Breslow: p<0.001
6 8 10 12
40
60
80
100
Baseline album in <40 g/L, n=21
Baseline album in ≥40 g/L, n=27
Figure  3. Kaplan-Meier curve demonstrating the cumulative probability for colectomy after primary non-response to infliximab stratified by infliximab 
concentration at Week 2 [A], Week 6 [B], baseline CRP [C], and baseline albumin [D]. CRP, C-reactive protein; PNR, primary non-response,;UC, ulcerative colitis.
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[n = 65] and had pancolitis [n = 58], and 23 had acute severe UC. 
Baseline characteristics of the patients are depicted in Table 1.
3.2. Long-term outcome of patients with UC and 
primary non-response to infliximab
After a median follow-up of 3.2 [IQR 1–6.3] years, 55 [55.6%] 
patients underwent colectomy. The 1st and the 5th year cumulative 
probabilities [standard error, SE] for colectomy after PNR to inflixi-
mab were 42.8 [0.052] and 62.4% [0.058], respectively. The median 
[95% CI] time to colectomy was 2 [0–4] years [Figure 1].
3.3. Factors associated with colectomy
Univariate [logrank test] analysis identified disease duration < 
3.2  years [p  <  0.001], acute severe UC [p  <  0.001], concomi-
tant corticosteroid treatment [p = 0.007], baseline CRP > 5 mg/l 
[p  <  0.001], baseline albumin < 40 g/l [p  <  0.001], infliximab 
concentration at Week 2 < 16.5 μg/ml [p = 0.001], and infliximab 
concentration < 5.3 μg/ml at Week 6 [p  <  0.001] as variables 
associated with colectomy [Table 2, Figures 2 and 3]. No multi-
collinearity between infliximab concentrations at Week 2 or 6 
was observed [VIF  =  1  <  3]. Multiple Cox regression analysis 
retained acute severe UC [p = 0.006], baseline albumin < 40 g/l 
[p  = 0.026], baseline CRP > 5mg/l [p  = 0.005], and infliximab 
concentration at Week 2 < 16.5 μg/ml [p = 0.034] as independent 
factors predicting colectomy [Table 2]. The relationship between 
baseline serum CRP and albumin with colectomy was further 
analysed by dividing baseline CRP levels and albumin into quar-
tiles. The higher baseline serum CRP and lower albumin quar-
tiles were associated with higher rates of colectomy [Figure  4 
A and B].
3.4. Infliximab concentrations and ATI associated 
with colectomy
Serum infliximab concentrations at Weeks 2 and 6 were lower in UC 
patients with colectomy compared with those without [Figure 4C]. 
A  ROC analysis identified infliximab concentration thresholds of 
16.5 and 5.3 μg/ml at Weeks 2 and 6, respectively, associated with 
colectomy [Supplementary Figure 1A, B]. The relationship between 
serum infliximab concentrations at Weeks 2 and 6 and colectomy 
was further analysed by dividing serum infliximab concentrations 
into quartiles. The lower infliximab serum concentration quartiles 
at Weeks 2 and 6 were generally associated with higher rates of 
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colectomy [Figure 4D]. Infliximab concentrations were not statisti-
cally significant different in patients on concomitant immunomodu-
lators compared with those without, both at Week 2 (median [IQR], 
21.4 [9.8–33.2] vs 21.9 [13.2–32], p = 0.960) and at Week 6 (18.3 
[6.4–25] vs 13.1 [3.8–20.7], p = 0.345, respectively).
Measurements of ATI were available in 44 patients during the 
induction therapy [either at Week 2 or at Week 6]; none of these 
patients had positive ATI. In one patient with undetectable inf-
liximab concentration ATI were negative, and in the remaining 43 
patients were considered inconclusive.
3.5. Long-term outcome of UC patients who 
continued on biologicals after PNR to infliximab
Following PNR to infliximab, 41 UC patients received 51 courses of 
biological therapy and were followed for a median of 2.5 [IQR 1.2–3.9] 
years [Figure 5]. The median [95% CI] time for relapse was 8.8 [1–16.5] 
months. For patients who failed to respond to IFX but subsequently 
responded to an alternative anti-TNF agent, the interval [median, IQR] 
was 30 [7–63] weeks. There was no statistically significant difference 
between switching to another anti-TNF agent and swapping to an out 
of anti-TNF class biological drug in terms of relapse [p logrank = 0.136, 
Figure 6A], although there was a marginally higher cumulative prob-
ability of relapse in patients switching to another anti-TNF agent com-
pared with those swapping to vedolizumab only [p logrank = 0.080, 
Figure 6B]. Moreover, the cumulative probability for PNR was higher 
in patients who switched to another anti-TNF agent compared with 
those swapping either to an out of anti-TNF class biological drug [p 
logrank = 0.022, HR = 5.3, 95% CI: 1.3–21.7], Figure 6C] or to vedoli-
zumab only [p logrank = 0.037 Figure 6D].
4. Discussion
Although anti-TNF therapy is effective for IBD, 10–30% of patients 
show PNR.5 The management of PNR to anti-TNF therapy is still 
empirical. Therapeutic options include surgery, switch to another 
anti-TNF agent and/or swapping to an out of class biological treat-
ment, such as vedolizumab which recently reached the pharmaceu-
tical market. Even after 20 years of use, little is known about the 
long-term outcome of patients with PNR to anti-TNF therapy.
We demonstrated that more than half of UC patients with PNR 
to infliximab will eventually undergo colectomy, especially those 
with acute severe UC, elevated baseline CRP levels, and lower base-
line albumin levels and infliximab concetrations during the induc-
tion phase, probably due to the high inflammatory burden at the 
start of infliximab therapy. Signs of severe baseline inflammation 
such as high CRP [ > 5 mg/l] and low albumin levels [ < 35 g/l] were 
previously shown to be independent predictors of colectomy in UC 
patients treated with infliximab.17 These factors negatively influ-
ence the pharmacokinetic profile of infliximab by inducing a higher 
non-immune clearance in IBD patients.12,16,23,24,25 Consequently, 
severely active disease in these patients may not be controlled by a 
standard induction regimen of infliximab [5 mg/kg, 0–2-6 week] or 
adalimumab [160/80 mg, 0-2 week] and may require higher doses 
to avoid PNR.15,26,27,28,29,30,31,32 However, based on analysis of inflixi-
mab serum concentration quartiles, 40–50% of patients needed a 
colectomy despite adequate drug concentrations. These patients may 
be characterised by a non TNF-driven disease, as previously descri
bed.33,34,35,36
Moreover, we showed that swapping to an out of class drug, such 
as vedolizumab, is probably better than switching to another anti-
TNF agent for the long-term management of UC patients with PNR 
to infliximab, as the latter therapeutic strategy is associated with a 
higher likelihood of relapse and PNR. A recent meta-analysis showed 
a remission rate of 30% in CD patients switching to another anti-
TNF agent,11 and a durable response to adalimumab in some UC 
patients with PNR to infliximab was also observed.14 Furthermore, 
the efficacy of adalimumab in patients with CD and PNR to inf-
liximab was 33–72% and 11–50% in terms of clinical response and 
remission, respectively, for up to 1 year of follow-up.5 These data 
demonstrate that some patients may still benefit from switching to 
Treatment courses of UC patients who continued on biologicals after PNR to iniximab
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Adalimumab, (N=18)•
•
•
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•
•
•
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•
Figure 5. Long-term outcome of UC patients who continued on biologicals after primary non-response to infliximab. PNR, primary non response; SAE, serious 
adverse event; SLR, secondary loss of response; TNF, tumour necrosis factor; UC, ulcerative colitis.
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another anti-TNF agent, suggesting that PNR to anti-TNF therapy 
may not be a class-effect phenomenon.4,37,38 However, swapping 
to an out of class drug rather than switching to another anti-TNF 
would be a more rational therapeutic approach for patients with 
adequate drug concentrations during the induction phase, suggest-
ing a nonTNF-driven inflammation.5 Vedolizumab was previously 
shown to be efficacious in UC patients with PNR to anti-TNF ther-
apy, although data regarding severe fulminant colitis are missing.39 
Additionally, studies from rheumatoid arthritis have demonstrated 
that patients with PNR to anti-TNF therapy had significantly higher 
drug retention for biological agents with a different mode of action 
compared with alternative anti-TNF agents, implying that these 
patients may have a non TNF-mediated disease.39,40
The main limitations of this study are its retrospective nature and 
the fact that infliximab concentrations were not available for all the 
patients. As a result, due the small sample size, a robust, consistent 
analysis on the influence of infliximab drug concentrations on the 
efficacy of either swapping to a different anti-TNF or switching to 
another anti-TNF following PNR to infliximab, although of great 
significance, was not feasible. Another limitation was the use of a 
drug-sensitive assay to measure ATI leading probably to an under-
estimation of the positive ATI patients.
In conclusion, this large, multi-centre study, reflecting real-life clin-
ical practice, indicates that more than half of UC patients with PNR 
to infliximab will eventually undergo colectomy, especially those with 
severe inflammation and low serum infliximab concentrations. The 
colectomy rate may be under-estimated and could be even higher in 
non-referral hospitals, since our study contacted three tertiary referral 
IBD centres with relatively large therapeutic armentaria and alterna-
tive treatment options [ertrolizumab, tofacitinib, other], used as rescue 
therapy, before a surgical intervention is applied. Prospective, large 
therapeutic drug monitoring [TDM] studies to clearly define the thera-
peutic window of infliximab induction therapy, and drug concentra-
tion thresholds for prediction of response following pharmacological 
interventions after PNR to anti-TNF therapy, progressing towards 
individual, personalised medicine, are certainly warranted.20, 41
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